AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 351218
Drug: Insulin treatment
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin treatment (adjusted dosage to achieve normoglycemia)
Trial: 351218
Drug: Fixed dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose of insulin
Trial: 7039378
Drug: Ticarcillin (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticarcillin (one 6 g dose at the start of the operation)
Trial: 7039378
Drug: Cephalothin (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalothin (three 2 g doses given at 4 hour intervals from the start of the operation)
Trial: 18372395
Drug: Solabegron 50
RxNorm normalized name: Solabegron
DrugBank: Solabegron (DB06190)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solabegron 50 mg twice daily
Trial: 18372395
Drug: Solabegron 200
RxNorm normalized name: Solabegron
DrugBank: Solabegron (DB06190)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solabegron 200 mg twice daily
Trial: 12875702
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg rosiglitazone once daily plus sulphonylurea
Trial: 12875702
Drug: 0.5 g
RxNorm normalized name: Gelatin Capsules, 10.5 gr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g metformin twice daily plus sulphonylurea
Trial: 10563066
Drug: Cerivastatin 0.025
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerivastatin 0.025 mg
Trial: 10563066
Drug: Cerivastatin 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerivastatin 0.05 mg
Trial: 10817086
Drug: Cerivastatin 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerivastatin 0.1 mg
Trial: 10563066
Drug: Cerivastatin (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerivastatin (all doses)
Trial: 10563066
Drug: Cerivastatin 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerivastatin 0.1 mg and 0.2 mg
Trial: 1957618
Drug: Milk cereal
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk cereal fortified with ferrous fumarate (7.5 mg/100 g)
Trial: 1957618
Drug: Milk cereal
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk cereal fortified with ferric-pyrophosphate (7.5 mg/100 g)
Trial: 10382188
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no nutritional supplement)
Trial: 6359383
Drug: ampicillin plus
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ampicillin plus cloxacillin (2 g of each daily for 6 days)
Trial: 6359383
Drug: ticarcillin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ticarcillin (5 g X 12, 8‐hourly)
Trial: 6359383
Drug: carbenicillin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: carbenicillin (10 g X 12, 8‐hourly)
Trial: 6359383
Drug: clindamycin (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: clindamycin (900 mg, 4 daily doses)
Trial: 6359383
Drug: clindamycin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: clindamycin plus netilmicin (90 mg, 4 daily doses)
Trial: 31206956
Drug: 0.2 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mL/kg 24% sucrose
Trial: 31206956
Drug: 0.5 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mL/kg 24% sucrose
Trial: 29230663
Drug: PEG‐rhG‐CSF 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐rhG‐CSF 100 µg/kg
Trial: 26796802
Drug: PEG‐rhG‐CSF 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐rhG‐CSF 6 mg
Trial: 29230663
Drug: PEG‐rhG‐CSF 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐rhG‐CSF 100 µg/kg and 6 mg
Trial: 25234339
Drug: 500 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/d of RRR‐α‐tocopherol
Trial: 25234339
Drug: 500 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/d of mixed tocopherols
Trial: 25234339
Drug: 500 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/d of vitamin C
Trial: 25234339
Drug: 1000 mg/d
RxNorm normalized name: RibaTab 1000 MG/day Compliance Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg/d of grape‐seed polyphenols
Trial: 15023611
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of vitamin C and polyphenols
Trial: 22391079
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate nasal spray (FFNS), 110 μg, daily for 1 year
Trial: 22391079
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate nasal spray (MFNS), 200 μg, daily for 1 year
Trial: 18629723
Drug: Quest plus
RxNorm normalized name: Quest Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quest plus placebo patch
Trial: 6166691
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (spontaneous decrease)
Trial: 25543426
Drug: Fentanyl citrate
RxNorm normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl citrate injection at auricular points (0.25 mL at each point)
Trial: 25543426
Drug: Subcutaneous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous fentanyl citrate injection in the deltoid muscle (1 mL)
Trial: 25543426
Drug: Subcutaneous sodium
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous sodium chloride injection in the deltoid muscle (1 mL)
Trial: 22351892
Drug: ω‐3 group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ω‐3 group (500‐mg daily fish oil supplement and canola-based margarines and cooking oil)
Trial: 22351892
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (500‐mg daily sunflower oil supplement and ω‐6 fatty acid-rich margarines and cooking oil)
Trial: 12837811
Drug: Docetaxel 75
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m2 and cisplatin 75 mg/m2 every 3 weeks (DC)
Trial: 12837811
Drug: Docetaxel 75
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m2 and carboplatin area under the curve of 6 mg/mL * min every 3 weeks (DCb)
Trial: 12837811
Drug: Vinorelbine 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine 25 mg/m2/wk and cisplatin 100 mg/m2 every 4 weeks (VC)
Trial: 8672316
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25% bupivacaine 1 ml kg‐1 with ketamine 0.5 mg kg‐1
Trial: 1751269
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25% bupivacaine 1 ml kg‐1
Trial: 1751269
Drug: ketamine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketamine 0.5 mg kg‐1 with normal saline 1 ml kg‐1
Trial: 6762741
Drug: Combination chemotherapeutic
RxNorm normalized name: ANTIBIOTICS AND CHEMOTHERAPEUTICS, COMBINATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapeutic regimen (cyclophosphamide, methotrexate, BCNU)
Trial: 6762741
Drug: Combination chemotherapeutic
RxNorm normalized name: ANTIBIOTICS AND CHEMOTHERAPEUTICS, COMBINATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapeutic regimen (cyclophosphamide, methotrexate, BCNU) plus intradermic BCG
Trial: 30859956
Drug: 1-day initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1-day initiation regimen (ALNCD + 30mg oral aripiprazole)
Trial: 30859956
Drug: 21-day oral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 21-day oral aripiprazole regimen
Trial: 28109729
Drug: Montelukast sodium
RxNorm normalized name: Montelukast Sodium
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Montelukast sodium and mometasone furoate (MF) therapy
Trial: 25772444
Drug: Insulin degludec/insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin degludec/insulin aspart (IDegAsp) at doses of 0.4, 0.6, or 0.8 U/kg
Trial: 16832639
Drug: Spa water
RxNorm normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spa water therapy at 37 degrees C for 20 min a day, 5 days a week, for 2 weeks
Trial: 16832639
Drug: Tap water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tap water therapy at 37 degrees C for 20 min a day, 5 days a week, for 2 weeks
Trial: 16832639
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of spa water therapy vs tap water therapy
Trial: 25236916
Drug: IVIG (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG (intravenous immunoglobulin)
Trial: 769147
Drug: Phase-release aspirin
RxNorm normalized name: aspirin Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase-release aspirin tablets given twice daily
Trial: 769147
Drug: Aspirin B.P.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin B.P. tablets given four times daily
Trial: 769147
Drug: Phase-release aspirin
RxNorm normalized name: aspirin Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase-release aspirin tablets
Trial: 26348699
Drug: Group Cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Cognitive Behavior Therapy (GCBT)
Trial: 23754735
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg twice daily
Trial: 23754735
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg twice daily
Trial: 23754735
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg twice daily
Trial: 23754735
Drug: 5 or
RxNorm normalized name: Acys-5 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 or 7.5 mg twice daily
Trial: 10856103
Drug: IRS-IV therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IRS-IV therapy (intensified therapy with a doubling of cyclophosphamide or ifosfamide equivalent dosing per cycle)
Trial: 10856103
Drug: IRS-IV therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IRS-IV therapy
Trial: 8635369
Drug: Flunitrazepam, 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam, 2 mg
Trial: 6426846
Drug: L-carnitine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine administration (20 and 25 mg/kg body weight)
Trial: 29805981
Drug: Diacerein 50
RxNorm normalized name: Diacerein 50 mg and glucosamine sulfate potassium chloride 1.5 g oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diacerein 50 mg
Trial: 22608375
Drug: Pharmacotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy and counseling for smoking cessation
Trial: 15309457
Drug: Perilla extract
RxNorm normalized name: Perilla frutescens whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perilla extract (PE) containing 200 mg rosmarinic acid (RA)
Trial: 7653809
Drug: Intermittent bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent bolus injections of propofol (10 mg) after an initial IV bolus of 0.3 mg/kg
Trial: 7653809
Drug: Conventional syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional syringe infusion pump (25-100 micrograms.kg-1.min-1) after an initial IV bolus of 0.3 mg/kg
Trial: 7653809
Drug: Target-controlled infusion
RxNorm normalized name: Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
DrugBank: Tagraxofusp (DB14731)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Target-controlled infusion (TCI) device with initial target concentration of 2 micrograms/mL adjusted between 1 and 4 micrograms/mL after an initial IV bolus of 0.3 mg/kg
Trial: 2173391
Drug: Dronabinol, 10
RxNorm normalized name: Dronabinol, 10 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dronabinol, 10 mg plus placebo q.i.d.
Trial: 2173391
Drug: Prochlorperazine, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prochlorperazine, 10 mg plus placebo q.i.d.
Trial: 2173391
Drug: Dronabinol plus
RxNorm normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dronabinol plus prochlorperazine, each 10 mg q.i.d.
Trial: 28732773
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral PrEP (tenofovir monotherapy or combination of tenofovir and emtricitabine)
Trial: 24875466
Drug: Early oral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early oral feeding (EOF) starting on the first postoperative day
Trial: 24875466
Drug: Late oral
RxNorm normalized name: Adalate Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late oral feeding (LOF) remaining nil by mouth until the return of bowel sounds
Trial: 17112855
Drug: Pentoxifylline (PTX)
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (PTX) 2 x 600 mg/d for 3 months (GI)
Trial: 11376256
Drug: 24 hour
RxNorm normalized name: Immune 24 Hour +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 hour two dose of 225 mL dilute contrast material
Trial: 11376256
Drug: 24 hour
RxNorm normalized name: Immune 24 Hour +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 hour five dose of 225 mL dilute contrast material
Trial: 11376256
Drug: 48 hour
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 48 hour four dose of 225 mL dilute contrast material
Trial: 11376256
Drug: 48 hour
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 48 hour six dose of 225 mL dilute contrast material
Trial: 11376256
Drug: 48 hour
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 48 hour seven dose of 225 mL dilute contrast material
Trial: 3566389
Drug: Multidose cold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidose cold high potassium cardioplegia (27 mEq of KCl/L)
Trial: 3566389
Drug: Initial cold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial cold high potassium (27 mEq/L) cardioplegia followed by boluses of cold low potassium (7 mEq of KCl/L) solution
Trial: 22751086
Drug: Rivastigmine (3-4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivastigmine (3-4.5 mg/d)
Trial: 15945136
Drug: Dietary supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplements usage
Trial: 11844632
Drug: Single-dose oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose oral tramadol (75 mg or 112.5 mg) plus acetaminophen (650 mg or 975 mg)
Trial: 11844632
Drug: Combination analgesics
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination analgesics (tramadol plus acetaminophen)
Trial: 11844632
Drug: Components alone
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Components alone (tramadol or acetaminophen)
Trial: 8522642
Drug: Orlistat (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat (120 mg three times daily for 6 days)
Trial: 7606629
Drug: Placebo (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (three times daily for 6 days)
Trial: 1781415
Drug: Zileuton (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zileuton (200 mg to 800 mg)
Trial: 6996930
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg clobazam (single daily dose)
Trial: 6996930
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg diazepam (3-times daily)
Trial: 11177119
Drug: Methyltestosterone (MT)
RxNorm normalized name: Methyltestosterone
DrugBank: Methyltestosterone (DB06710)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methyltestosterone (MT) 40 mg/d for 3 days, then 240 mg/d for 3 days
Trial: 9394322
Drug: Dermatan sulphate
RxNorm normalized name: Dermatan sulphate
DrugBank: Dermatan sulfate (DB15880)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dermatan sulphate (DS) at 4 mg/kg as a predialysis intravenous bolus followed by continuous infusion of 0.65 mg/kg/h
Trial: 28337949
Drug: Masters‐Johnson sex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Masters‐Johnson sex therapy (MJST)
Trial: 26194791
Drug: Op Volle
RxNorm normalized name: Schinus molle pollen
DrugBank: Schinus molle pollen (DB10483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Op Volle Kracht (OVK) plus Treatment as Usual (TAU)
Trial: 18437408
Drug: Control (combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (combination of five different components)
Trial: 14565783
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin (acetylsalicylic acid) therapy
Trial: 10958177
Drug: Glandular symptoms
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glandular symptoms (G)
Trial: 8840054
Drug: General anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anaesthesia followed by postoperative intravenous analgesia (GA)
Trial: 15772563
Drug: Raloxifene 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene 150 mg/d
Trial: 9848300
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogen (CEE) 0.625 mg/d
Trial: 8153939
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate 1000 micrograms twice daily
Trial: 28825570
Drug: self-injection
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: self-injection
Trial: 28825570
Drug: home treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: home treatment
Trial: 28825570
Drug: early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: early treatment decision
Trial: 28825570
Drug: sharing treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sharing treatment dose
Trial: 28825570
Drug: access to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: access to medication
Trial: 26214772
Drug: Rituximab (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (375 mg/m2 via four weekly intravenous drip)
Trial: 26214772
Drug: Vincristine (0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vincristine (0.02 mg/kg by intravenous drip once a week for three months)
Trial: 21261975
Drug: Early parenteral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early parenteral nutrition (PN) initiated within 24-48 hours after ICU admission
Trial: 21261975
Drug: Late parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late parenteral nutrition (PN) initiated on day 8 when caloric target is not reached
Trial: 16514301
Drug: Atazanavir/ritonavir (300/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atazanavir/ritonavir (300/100 mg) QD
Trial: 16514301
Drug: Lopinavir/ritonavir (400/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir (400/100 mg) BID
Trial: 14641992
Drug: Standard postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard postoperative chemotherapy
Trial: 14641992
Drug: Epidermal growth
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidermal growth factor receptor/tyrosine kinase inhibitor gefitinib
Trial: 14641992
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of new approaches and standard therapy
Trial: 10837389
Drug: Vigabatrin (VGB)
DrugBank: Vigabatrin (DB01080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vigabatrin (VGB) therapy
Trial: 8451470
Drug: Midazolam-Propofol combination
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Midazolam-Propofol combination
Trial: 28729473
Drug: Automated oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated oxygen titration
Trial: 24408211
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg mCPP
Trial: 24408211
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg mCPP
Trial: 10526939
Drug: Nitrate infusion
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrate infusion (isosorbide dinitrate: ISDN or nitroglycerin: TNG) for 30 minutes (group A)